Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1996 1
1997 3
1998 3
1999 6
2000 6
2001 6
2002 10
2003 12
2004 20
2005 38
2006 34
2007 29
2008 26
2009 18
2010 16
2011 23
2012 19
2013 24
2014 12
2015 13
2016 14
2017 14
2018 16
2019 12
2020 14
2021 19
2022 6
2023 12
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

386 results

Results by year

Filters applied: . Clear all
Page 1
Targeting acetylcholine signaling modulates persistent drug tolerance in EGFR-mutant lung cancer and impedes tumor relapse.
Nie M, Chen N, Pang H, Jiang T, Jiang W, Tian P, Yao L, Chen Y, DeBerardinis RJ, Li W, Yu Q, Zhou C, Hu Z. Nie M, et al. J Clin Invest. 2022 Oct 17;132(20):e160152. doi: 10.1172/JCI160152. J Clin Invest. 2022. PMID: 36048538 Free PMC article.
Strikingly, pharmacologically targeting ACh/M3R signaling with an FDA-approved drug, darifenacin, retarded tumor relapse in vivo. Mechanistically, upregulated ACh metabolism mediated drug tolerance in part through activating WNT signaling via ACh muscarinic receptor 3 (M3R …
Strikingly, pharmacologically targeting ACh/M3R signaling with an FDA-approved drug, darifenacin, retarded tumor relapse in vivo. Mec …
Darifenacin.
[No authors listed] [No authors listed] 2023 Jul 12. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2023 Jul 12. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644105 Free Books & Documents. Review.
Darifenacin is an anticholinergic and antispasmotic agent used to treat urinary incontinence and overactive bladder syndrome. Darifenacin has not been implicated in causing liver enzyme elevations or clinically apparent acute liver injury....
Darifenacin is an anticholinergic and antispasmotic agent used to treat urinary incontinence and overactive bladder syndrome. Dari …
Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults.
Stoniute A, Madhuvrata P, Still M, Barron-Millar E, Nabi G, Omar MI. Stoniute A, et al. Cochrane Database Syst Rev. 2023 May 9;5(5):CD003781. doi: 10.1002/14651858.CD003781.pub3. Cochrane Database Syst Rev. 2023. PMID: 37160401 Review.
Nine anticholinergic drugs were included in these studies: darifenacin; fesoterodine; imidafenacin; oxybutynin; propantheline; propiverine; solifenacin; tolterodine and trospium. ...
Nine anticholinergic drugs were included in these studies: darifenacin; fesoterodine; imidafenacin; oxybutynin; propantheline; propiv …
The clinical pharmacokinetics of darifenacin.
Skerjanec A. Skerjanec A. Clin Pharmacokinet. 2006;45(4):325-50. doi: 10.2165/00003088-200645040-00001. Clin Pharmacokinet. 2006. PMID: 16584282 Review.
The absolute bioavailability of darifenacin from 7.5 and 15 mg PR tablets was estimated to be 15.4% and 18.6%, respectively. ...Several possibly important drug-drug interactions have been identified with darifenacin, including ketoconazole, erythromycin and fluconaz …
The absolute bioavailability of darifenacin from 7.5 and 15 mg PR tablets was estimated to be 15.4% and 18.6%, respectively. ...Sever …
Darifenacin: in the treatment of overactive bladder.
Croom KF, Keating GM. Croom KF, et al. Drugs Aging. 2004;21(13):885-92; discussion 893-4. doi: 10.2165/00002512-200421130-00005. Drugs Aging. 2004. PMID: 15493952 Review.
Darifenacin was generally well tolerated in clinical trials. The most common adverse events were dry mouth and constipation. CNS tolerability appeared to be similar to that of placebo. Darifenacin had no adverse effect on cognitive function in healthy elderly volunt …
Darifenacin was generally well tolerated in clinical trials. The most common adverse events were dry mouth and constipation. CNS tole …
Darifenacin: Pharmacology and clinical usage.
Steers WD. Steers WD. Urol Clin North Am. 2006 Nov;33(4):475-82, viii. doi: 10.1016/j.ucl.2006.06.007. Urol Clin North Am. 2006. PMID: 17011383 Review.
Darifenacin is one of several recently approved antimuscarinics for the treatment of overactive bladder (OAB) and urge urinary incontinence. Darifenacin is an effective drug for the treatment of OAB and is tolerated by patients. ...
Darifenacin is one of several recently approved antimuscarinics for the treatment of overactive bladder (OAB) and urge urinary incont …
Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis.
He W, Huang G, Cui W, Tian Y, Sun Q, Zhao X, Zhao Y, Li D, Liu X. He W, et al. Int Braz J Urol. 2023 Sep-Oct;49(5):535-563. doi: 10.1590/S1677-5538.IBJU.2023.0158. Int Braz J Urol. 2023. PMID: 37506033 Free PMC article. Review.
Compared to placebo, imidafenacin 0.1mg showed a significantly increased incidence in hypertension, solifenacin 10mg in urinary tract infection, fesoterodine 4/8mg and darifenacin 15mg in headache. CONCLUSION: Solifenacin showed better efficacy. ...
Compared to placebo, imidafenacin 0.1mg showed a significantly increased incidence in hypertension, solifenacin 10mg in urinary tract infect …
Darifenacin in the treatment of overactive bladder.
Haab F. Haab F. Drugs Today (Barc). 2005 Jul;41(7):441-52. doi: 10.1358/dot.2005.41.7.891719. Drugs Today (Barc). 2005. PMID: 16193097 Review.
Darifenacin is a novel muscarinic M(3) selective receptor antagonist developed for the once-daily treatment of overactive bladder, a chronic, debilitating and highly prevalent condition affecting adults of all ages. ...Hence, in conjunction with data showing that this agen …
Darifenacin is a novel muscarinic M(3) selective receptor antagonist developed for the once-daily treatment of overactive bladder, a …
Suppression of voltage-gated K(+) channels by darifenacin in coronary arterial smooth muscle cells.
Seo MS, An JR, Jung HS, Kang M, Heo R, Han ET, Yang SR, Park H, Jung WK, Choi IW, Bae YM, Na SH, Park WS. Seo MS, et al. Eur J Pharmacol. 2021 Jan 15;891:173707. doi: 10.1016/j.ejphar.2020.173707. Epub 2020 Oct 31. Eur J Pharmacol. 2021. PMID: 33137332
Darifenacin slowed the time constants of recovery from inactivation. ...Darifenacin substantially induced vasocontraction. Furthermore, darifenacin caused membrane depolarization and decreased coronary blood flow. ...
Darifenacin slowed the time constants of recovery from inactivation. ...Darifenacin substantially induced vasocontraction. Fur …
386 results